LPCN — Lipocine Cashflow Statement
0.000.00%
- $30.22m
- $5.58m
- -$2.85m
- 33
- 22
- 94
- 48
Annual cashflow statement for Lipocine, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -13 | -21 | -0.634 | -10.8 | -16.4 |
Depreciation | |||||
Non-Cash Items | 0.856 | 4.14 | 0.817 | -0.296 | -0.511 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.469 | 1.52 | -4.59 | -0.924 | 4.97 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -11.7 | -15.3 | -4.41 | -12 | -11.9 |
Capital Expenditures | — | — | -0.008 | -0.134 | -0.013 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 3 | 3.89 | -43.8 | 14.4 | 13.1 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 3 | 3.89 | -43.8 | 14.3 | 13.1 |
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 10.3 | 20.9 | 26.9 | -2.13 | 0.405 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.65 | 9.49 | -21.3 | 0.198 | 1.62 |